Loading
AVAglio tested adding the anti-blood-vessel drug bevacizumab to standard radiotherapy and chemotherapy for newly diagnosed glioblastoma; the tumours took longer to grow on scans, but people did not live any longer, so bevacizumab is not used up front for this cancer.
AVAglio was a double-blind placebo-controlled phase 3 trial in newly diagnosed glioblastoma. After surgery or biopsy, patients received radiotherapy with concurrent and adjuvant temozolomide and were randomised to bevacizumab or placebo throughout, followed by single-agent maintenance.
Bevacizumab prolonged progression-free survival, one of the two primary endpoints, but did not improve overall survival, the other. The parallel US trial RTOG 0825 reached the same conclusion, and together they closed the question of first-line bevacizumab in glioblastoma; the drug remains in use for symptomatic relief and at recurrence, where its 2009 accelerated approval was granted.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
921 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (investigator-assessed)primary | Bevacizumab + radiotherapy-temozolomide | 458 | 10.6 months | 0.64 (0.55 to 0.74) | <0.001 | link |
| Placebo + radiotherapy-temozolomide | 463 | 6.2 months | ||||
| Overall survivalprimary | Bevacizumab + radiotherapy-temozolomide | 458 | Medians not reported in the abstract | 0.88 (0.76 to 1.02) | 0.10 | link |
| Placebo + radiotherapy-temozolomide | 463 | - | ||||
| Overall survival at 2 years | Bevacizumab + radiotherapy-temozolomide | 458 | 33.9% | - | 0.24 | link |
| Placebo + radiotherapy-temozolomide | 463 | 30.1% | ||||
| Grade 3 or higher adverse events | Bevacizumab + radiotherapy-temozolomide | - | 66.8% | - | - | link |
| Placebo + radiotherapy-temozolomide | - | 51.3% |
Shares Temozolomide, Roche / Genentech, Anti-angiogenic therapy, Glioma & glioblastoma and the tag subtype-trials.
Shares Brain and spinal cord tumours (all types), Temozolomide, Glioma & glioblastoma and the tag subtype-trials.
Shares Anti-angiogenic therapy, Monoclonal antibodies and the tag subtype-trials.
Shares Temozolomide, Glioma & glioblastoma and the tag subtype-trials.
Shares Roche / Genentech, Monoclonal antibodies and the tag subtype-trials.
Shares Anti-angiogenic therapy and the tag subtype-trials.
Shares Roche / Genentech and the tag subtype-trials.
Shares Roche / Genentech and the tag subtype-trials.